Revenues for Alpharma's active pharmaceutical ingredient (API)
division went up by around $30m over fiscal 2006, over half of
which was generated by products previously part of the company's
divested generics business.
Researchers have demonstrated the effectiveness of a new drug for
treating infections caused by Staphylococcus aureus bacteria
representing the first drug of its kind to be FDA approved in two
Arpida has announced it has successfully completed a Phase I
clinical trial with oral iclaprim in a capsule formulation. This
broad-spectrum antibiotic targets infections requiring hospital
treatment, including those caused by methicillin-resistant...
Acolyte Biomedica introduces a new platform for its MRSA test,
which promises to set the benchmark for laboratory-based screening
of the bacterium by confirming negatives in five hours and
positives within 24 hours.
The latest research included in the proceedings of the Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC) means
that antibiotic treatments and management therapies feature
strongly in DrugResearcher’s round-up...
Greenbridge Environmental Control of the UK has introdueced a new
cleaner and disinfectant agent, suitable for commercial scale
applications, that is claimed to be the first non-toxic product of
Data from the first drug in a new class of antibiotics was
presented at this year's ECCMID conference, which showed the drug
demonstrated its efficacy against a wide variety of gram-positive
and gram-negative bacteria including...
The US Food and Drug Administration (FDA) has given clearance to a
new product, which simplifies the process, offers improved
specificity and decreases the time to result in the identification
of methicillin-resistant Staphyloccus...
Researchers have identified and tested an anti-sense
oligonucleotide sequence that will kill strains of Methicillin
Resistant (MRSA) and Vancomycin-resistant (VRSA) Staphylococcus
aureus, which continue to cause a serious public health...
A laboratory test that is able to detect methicillin resistant
Staphylococcus aureus (MRSA) a day earlier then traditional
antimicrobial susceptibility testing (AST) gives fresh impetus to
treatment and infection control efforts that...
A yeast encapsulation technology developed by UK company Micap is
at the heart of a new strategy for controlling
methicillin-resistant Staphylococcus aureus, the 'superbug'
that is emerging as a major threat in hospitals...
Nabi Biopharmaceuticals saw biopharmaceutical product sales -
driven by strong growth in sales of Nabi-HB - reaching record
levels of $89.5 million (€83m) in 2002, a 22 per cent increase from